Compare

IGF-1 DES vs IGF-1 LR3

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

IGF-1 DES

2337 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 51% · Mixed 32% · Unfavorable overall 17%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Skin appearance
48
Appetite control
39
Energy
127
Mood
93
Focus
112

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Headache
144
GI discomfort
118
Dizziness
92
Fatigue
89
Nausea
111

Self-reported dose per injection

Median bucket: 0.4–0.6 mg · Most common: 0.2–0.4 mg

Reports span 0.05–2 mg

0.05–0.1 mg
7
0.1–0.2 mg
15
0.2–0.4 mg
18
0.4–0.6 mg
14
0.6–1 mg
8
1–2 mg
2

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing21stacking19side effects17igf-1 des20

How repeat users are trending

Among repeat reporters, 61% said they felt similar to their last entry, 43% more positive, and 21% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 23 days · Based on 514 repeat reporters

IGF-1 LR3

764 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 68% · Mixed 16% · Unfavorable overall 16%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Mood
-117
Focus
-162
Sleep quality
-145
Lean mass
-166
Joint comfort
-101

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Fatigue
-21
Nausea
-83
Water retention
0
Appetite loss
10
Injection site reaction
-101

Self-reported dose per injection

Median bucket: 100–200 mcg · Most common: 100–200 mcg

Reports span 25–600 mcg

25–50
2
50–100
13
100–200
22
200–400
11
400–600
2

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing48stacking31side effects34igf-1 lr322

How repeat users are trending

Among repeat reporters, 63% said they felt similar to their last entry, 42% more positive, and 18% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 28 days · Based on 168 repeat reporters

Sources (10)

Published sources linked on the IGF-1 DES and IGF-1 LR3 wiki pages.

  1. PubMed

    Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I

    Ballard FJ, Wallace JC, Francis GL, et al. Int J Biochem Cell Biol. 1996

    Source
    Wiki study page →
  2. PubMed

    Enhanced potency of truncated insulin-like growth factor-I (des(1-3)IGF-I) relative to IGF-I in lit/lit mice

    Gillespie C, Read LC, Bagley CJ, et al. J Endocrinol. 1990

    Source
    Wiki study page →
  3. PubMed

    In vivo actions of IGF analogues with poor affinities for IGFBPs: metabolic and growth effects in pigs of different ages and GH responsiveness

    Walton PE, Dunshea FR, Ballard FJ. Prog Growth Factor Res. 1995

    Source
    Wiki study page →
  4. PubMed

    IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys

    Tomas FM, Walton PE, Dunshea FR, et al. J Endocrinol. 1997

    Source
    Wiki study page →
  5. PubMed

    Insulin-like growth factor-I and its N-terminal modified analogues induce marked gut growth in dexamethasone-treated rats

    Read LC, Tomas FM, Howarth GS, et al. J Endocrinol. 1992

    Source
    Wiki study page →
  6. ClinicalTrials.gov

    des(1-3)IGF-1 / IGF-1 DES studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  7. PubMed

    Insulin-like growth factor-I and its binding proteins in sport and exercise medicine

    Baxter RC. Endocr Rev. 2011

    Source
    Wiki study page →
  8. ClinicalTrials.gov

    IGF-1 LR3 studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  9. PubMed

    Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice

    Engel MG, Narayan S, Cui MH, et al. Journal of Alzheimer's disease : JAD. 2025

    Source
    Wiki study page →
  10. PubMed

    Revolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration

    Yavuz E, Sağır MS, Ercan A, et al. International journal of biological macromolecules. 2025

    Source
    Wiki study page →